Zastrzyk z toksyny botulinowej na zmarszczki mimiczne

Źródła:

1. American Society for Aesthetic Plastic Surgery. Cosmetic Surgery National Data Bank statistics 2013. http://www.surgery.org/media/statistics. Accessed February 26, 2014.
2. Small R. Aesthetic procedures in office practice. Am Fam Physician. 2009;80(11):1231-1237.
3. Carruthers JD, Carruthers A. The use of botulinum toxin type A in the upper face. Facial Plast Surg Clin North Am. 2006;14(3):253-260.
4. Cavallini M, Cirillo P, Fundarò SP, et al. Safety of botulinum toxin A in aesthetic treatments: a systematic review of clinical studies. Dermatol Surg. 2014;40(5):525-536.
5. Stotland MA, Kowalski JW, Ray BB. Patient-reported benefit and satisfaction with botulinum toxin type A treatment of moderate to severe glabellar rhytides: results from a prospective open-label study. Plast Reconstr Surg. 2007;120(5):1386-1393 , discussion 1394.
6. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29(23):1761-1768.
7. Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993;365(6442):160-163.
8. FDA approves Botox Cosmetic to improve the appearance of crow’s feet lines [news release]. Silver Springs, Md.: U.S. Food and Drug Administration; September 11, 2013. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm367662.htm. Accessed April 18, 2014.
9. Carruthers JA, Lowe NJ, Menter MA, et al.; BOTOX Glabellar Lines I Study Group. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46(6):840-849.
10. Carruthers A, Carruthers J, Cohen JL. A prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatol Surg. 2003;29(5):461-467.
11. Lowe NJ, Lask GP, Yamauchi PS, Moore D. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow’s feet. J Am Acad Dermatol. 2002;47(6):834-840.
12. Michaels BM, Csank GA, Ryb GE, Eko FN, Rubin A. Prospective randomized comparison of onabotulinumtoxinA (Botox) and abobotulinumtoxinA (Dysport) in the treatment of forehead, glabellar, and periorbital wrinkles. Aesthet Surg J. 2012;32(1):96-102.
13. Sattler G, Callander MJ, Grablowitz D, et al. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg. 2010;36(suppl 4):2146-2154.
14. Ascher B, Talarico S, Cassuto D, et al. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)–Part I: upper facial wrinkles. J Eur Acad Dermatol Venereol. 2010;24(11):1278-1284.
15. Small R, Hoang D. A Practical Guide to Botulinum Toxin Procedures. Philadelphia, Pa.: Lippincott Williams & Wilkins; 2012.
16. Klein AW. Contraindications and complications with the use of botulinum toxin. Clin Dermatol. 2004;22(1):66-75.
17. Carruthers J, Fagien S, Matarasso SL Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast Reconstr Surg. 2004;114(6 suppl):1S-22S.
18. Dysport (abobotulinumtoxin A) injection [prescribing information]. Scottsdale, Ariz.: Medicis Aesthetics, Inc.; 2012 http://pi.medicis.us/dysport.pdf. Accessed April 18, 2014.
19. Bakshi E, Hartstein ME. Compositional differences among commercially available botulinum toxin type A. Curr Opin Ophthalmol. 2011;22(5):407-412.
20. Dessy LA, Fallico N, Mazzocchi M, Scuderi N. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products. Am J Clin Dermatol. 2011;12(6):377-388.
21. Kassir R, Kolluru A, Kassir M. Triple-blind, prospective, internally controlled comparative study between abobotulinumtoxinA and onabotulinumtoxinA for the treatment of facial rhytids. Dermatol Ther (Heidelb). 2013;3(2):179-189.
22. Small R. Aesthetic Principles and Consultation. In: Usatine R, Pfenninger J, Stuhlberg D, Small R, eds. Dermatologic and Cosmetic Procedures in Office Practice. Philadelphia, Pa.: Elsevier/Saunders; 2012:230–240.
23. Ciocon JO, Ciocon DG, Galindo DJ. Dietary supplements in primary care. Botanicals can affect surgical outcomes and follow-up. Geriatrics. 2004;59(9):20-24.
24. Small R. Botulinum Toxin. In: Usatine R, Pfenninger J, Stuhlberg D, Small R, eds. Dermatologic and Cosmetic Procedures in Office Practice. Philadelphia, Pa.: Elsevier/Saunders; 2012:248–258.
25. Prager W, Wissmüller E, Kollhorst B, Williams S, Zschocke I. Comparison of two botulinum toxin type A preparations for treating crow’s feet: a split-face, double-blind, proof-of-concept study. Dermatol Surg. 2010;36(suppl 4):2155-2160.
26. Edward M, Zimmerman. Botolinum toxin. In: Pfenninger JL, Fowler GC, eds. Pfenninger and Fowler’s Procedures for Primary Care. Philadelphia, Pa.: Elsevier/Saunders; 2012:363–372.
27. Beer KR, Boyd C, Patel RK, Bowen B, James SP, Brin MF. Rapid onset of response and patient-reported outcomes after onabotulinumtoxinA treatment of moderate-to-severe glabellar lines. J Drugs Dermatol. 2011;10(1):39-44.
28. Small R. Botulinum toxin type A for facial rejuvenation. In: Mayeaux E, ed. The Essential Guide to Primary Care Procedures. Philadelphia, Pa.: Lippincott Williams & Wilson; 2009:200–213.
29. Flynn TC. Botulinum toxin: examining duration of effect in facial aesthetic applications. Am J Clin Dermatol. 2010;11(3):183-199.
30. Cox SE, Adigun CG. Complications of injectable fillers and neurotoxins. Dermatol Ther. 2011;24(6):524-536.
31. Klein AW. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg. 2003;29(5):549-556 , discussion 556.
32. Wollina U, Konrad H. Managing adverse events associated with botulinum toxin type A: a focus on cosmetic procedures. Am J Clin Dermatol. 2005;6(3):141-150.
33. Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004;20(7):981-990.
34. Alam M, Arndt KA, Dover JS. Severe, intractable headache after injection with botulinum a exotoxin: report of 5 cases. J Am Acad Dermatol. 2002;46(1):62-65.
35. Toback SL. Medical emergency preparedness in office practice. Am Fam Physician. 2007;75(11):1679-1684.
36. Naumann M, Carruthers A, Carruthers J, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX^®) across multiple indications. Mov Disord. 2010;25(13):2211-2218.
37. Botox cosmetic (onabotulinumtoxinA) for injection, for intramuscular use [prescribing information]. Irvine, Calif.: Allergen, Inc.; 2013. http://www.allergan.com/assets/pdf/botox_cosmetic_pi.pdf. Accessed February 26, 2014.
38. U.S. Food and Drug Administration. Information for healthcare professionals: onabotulinumtoxinA (marketed as Botox/Botox Cosmetic), abobotulinumtoxinA (marketed as Dysport) and rimabotulinumtoxinB (marketed as Myobloc). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174949.htm. Accessed February 20 2013.
39. . Accessed February 26, 2014. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM165110.pdf
40. Derksen DJ. Anaphylaxis. In: Pfenninger JL, Fowler GC, eds. Pfenninger and Fowler’s Procedures for Primary Care. Philadeplhia, Pa.: Mosby Elsevier; 2011:1507–1509.
41. Nong LB, He WQ, Xu YH, et al. Severe respiratory failure after injection of botulinum toxin: case report and review of the literature [in Chinese]. Zhongus Jie He He Hu Xi Za Zhi. 2008;31(5):369-371.
42. Souayah N, Karim H, Kamin SS, McArdle J, Marcus S. Severe botulism after focal injection of botulinum toxin. Neurology. 2006;67(10):1855-1856.
43. Chertow DS, Tan ET, Maslanka SE, et al. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA. 2006;296(20):2476-2479.

Przetłumaczono:

Rebecca Small, Botulinum toxin injection for facial wrinkles, Am Fam Physician, 2014 Aug 1;90(3):168-75. https://pubmed.ncbi.nlm.nih.gov/25077722/

Strony: 1 2